Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilobelimab in early severe sepsis or septic shock
NCT02246595Phase 2Completed
- Sponsor
- InflaRx
- Start
- Apr 2014
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vilobelimab in sepsis, septic shock, sponsored by InflaRx. Started Apr 2014; status: completed.
02
Drugs
vilobelimab
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT02246595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02246595.